Welcome to our dedicated page for HALOZYME THERAPEUTICS SEC filings (Ticker: HALO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on HALOZYME THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into HALOZYME THERAPEUTICS's regulatory disclosures and financial reporting.
HALO submitted a Form 144 notice reporting proposed sales of Common stock and disclosing a recent sale. The filing shows a reported sale by Cortney A. Caudill of 20,000 shares on 03/09/2026 for $1,356,062. The notice lists several issuances/vestings and an option exercise with quantities of 4,663, 1,546, and 2,648 shares tied to vesting or exercise dates in 2024–2026.
Morgan Stanley Smith Barney LLC reports a Rule 144 sale notice for 20,000 common shares. The filing states the shares relate to an exercise of options under a registered plan and lists the transaction date as 03/09/2026 on NASDAQ. The filing indicates cash as the consideration and names Morgan Stanley Smith Barney LLC Executive Financial Services as the broker.
HALOZYME THERAPEUTICS, INC. President and CEO Helen Torley reported a combination of option exercises and share sales. Over March 2–4, 2026, she exercised options to acquire 50,000 shares of common stock at an exercise price of $12.07 per share.
She then sold 50,000 shares of common stock in multiple open‑market transactions under a pre‑established Rule 10b5‑1 trading plan, at weighted average prices within ranges between $68.22 and $71.36 per share. After these transactions, she directly owned 767,780 common shares.
HALOZYME THERAPEUTICS, INC. senior vice president and chief operating officer Cortney Caudill reported routine equity award activity. On February 20, 2026, 2,666 Restricted Stock Units vested and were settled into 2,666 shares of common stock, reflecting an exercise or conversion of derivative securities at a stated price of $0.0000 per share.
To cover tax withholding obligations from this vesting, 1,037 common shares were automatically withheld by the issuer at a price of $70.98 per share, as noted in the footnotes. After these transactions, Caudill directly owned 14,366 shares of common stock and 7,998 Restricted Stock Units. These movements reflect compensation-related settlements and tax withholding rather than open-market buying or selling.
Halozyme Therapeutics SVP and Chief Legal Officer Mark Howard Snyder reported multiple equity compensation events. On February 20 and 23, 2026, restricted stock units vested and were settled into 5,332 and 7,011 shares of common stock, respectively, through derivative exercises at $0.00 per share.
To satisfy tax withholding obligations, the issuer withheld 2,876 shares at $70.98 and 3,782 shares at $70.64, recorded as tax-withholding dispositions rather than open-market sales. After these transactions, Snyder directly owned 47,610 shares of Halozyme common stock.
Halozyme Therapeutics SVP & CFO Nicole LaBrosse reported equity award vesting and related tax-withholding transactions. On February 23, 6,688 Performance Stock Units were exercised into 6,688 shares of common stock, and 3,608 shares were withheld at $70.64 per share to cover taxes. On February 20, 5,332 Restricted Stock Units vested into 5,332 common shares, with 2,876 shares withheld at $70.98 per share for tax obligations. After these transactions, she directly held 38,494 shares of common stock, 36,357 Performance Stock Units, and 15,995 Restricted Stock Units.
HALOZYME THERAPEUTICS, INC. President and CEO Helen Torley reported equity compensation activity involving restricted stock units and related common stock. On February 20 and 23, 2026, restricted stock units vested and were settled into a total of 22436 and 16757 shares of common stock through derivative exercises.
On both dates, a portion of the newly delivered common shares, 9040 and 12104 shares respectively, was automatically withheld by the issuer to cover tax withholding obligations at prices of $70.98 and $70.64 per share, rather than sold in open‑market transactions. After these transactions, Torley directly owned 767780 shares of common stock and 44872 restricted stock units.
Snyder Mark Howard reported multiple insider transaction types in a Form 4 filing for HALO. The filing lists transactions totaling 42,692 shares at a weighted average price of $79.44 per share. Following the reported transactions, holdings were 4,796 shares.
LaBrosse Nicole reported multiple insider transaction types in a Form 4 filing for HALO. The filing lists transactions totaling 60,440 shares at a weighted average price of $79.44 per share. Following the reported transactions, holdings were 5,329 shares.
Torley Helen reported multiple insider transaction types in a Form 4 filing for HALO. The filing lists transactions totaling 226,153 shares at a weighted average price of $79.44 per share. Following the reported transactions, holdings were 16,874 shares.